REFERENCES

ADRIANA.Code (Version 2.0). (2006). Erlangen, Germany: Molecular Networks GmbH Computerchemie. Retrieved from https://www.molecular-networks.com/products/adrianacode

Agarwal, P. K., Billeter, S. R., Rajagopalan, P. T. R., Benkovic, S. J., & Hammes-Schiffer, S. (2002). Network of coupled promoting motions in enzyme catalysis. *Proc Natl Acad Sci USA, 99*(5), 2794-2799.

Agrawal, V. K., Sohgaura, R., & Khadikar, P. V. (2002). QSAR studies on biological activity of piritrexim analogues against pc DHFR. *Bioorg Med Chem, 10*(9), 2919-2926.

Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., & Chang, G. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. *Science, 323*(5922), 1718-1722.

Almajano, M. P., Carbó, R., Jiménez, J. A. L., & Gordon, M. H. (2008). Antioxidant and antimicrobial activities of tea infusions. *Food Chem, 108*(1), 55-63.

Amaro, R. E., & Li, W. W. (2010). Emerging methods for ensemble-based virtual screening. *Curr Top Med Chem, 10*(1), 3-13.

Ambudkar, S. V., Cardarelli, C. O., Pashinsky, I., & Stein, W. D. (1997). Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. *J Biol Chem, 272*(34), 21160-21166.

Ampasavate, C., Sotanaphun, U., Phattanawasin, P., & Piyapolrungroj, N. (2010). Effects of *Curcuma* spp. on P-glycoprotein function. *Phytomedicine, 17*(7), 506-512.

An, G., & Morris, M. (2010). Herbal supplement-based interactions. In K. S. Pang, A. D. Rodrigues, & R. M. Peter (Eds.), *Enzyme- and Transporter-Based Drug-Drug Interactions* (pp. 555-584): Springer New York.

Armstrong, N., Sun, Y., Chen, G. Q., & Gouaux, E. (1998). Structure of a glutamate-receptor ligand-binding core in complex with kainate. *Nature, 395*(6705), 913-917.

Asgaonkar, K. D., Mote, G. D., & Chitre, T. S. (2013). QSAR and molecular docking studies of oxadiazole-ligated pyrrole derivatives as enoyl-ACP (CoA) Reductase Inhibitors. *Sci Pharm, 82*(1), 71-85.

Auyeung, K. K. W., & Ko, J. K. S. (2010). Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. *Invest New Drugs, 28*(1), 1-13.

Badhan, R., & Penny, J. (2006). *In silico* modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. *Eur J Med Chem, 41*(3), 285-295.

Bakken, G. A., & Jurs, P. C. (2000). Classification of Multidrug-Resistance Reversal Agents Using Structure-Based Descriptors and Linear Discriminant Analysis. *J Med Chem, 43*(23), 4534-4541.

Balimane, P. V., Han, Y. H., & Chong, S. (2006). Current industrial practices of assessing permeability and P-glycoprotein interaction. *AAPS J, 8*(1), E1-13.

Bansal, T., Jaggi, M., Khar, R. K., & Talegaonkar, S. (2009). Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. *J Pharm Pharm Sci, 12*(1), 46-78.

Barnes, P. M., Bloom, B., & Nahin, R. L. (2008). Complementary and alternative medicine use among adults and children: United States, 2007. *Natl Health Stat Report*, (12), 1-23.

Barreca, M. L., De Luca, L., Iraci, N., Rao, A., Ferro, S., Maga, G., & Chimirri, A. (2007). Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. *J Chem Inf Model, 47*(2), 557-562.

Becker, J. P., Depret, G., Van Bambeke, F., Tulkens, P., & Prevost, M. (2009). Molecular models of human P-glycoprotein in two different catalytic states. *BMC Struct Bio, 9*(1), 3.

Benet, L. Z., Cummins, C. L., & Wu, C. Y. (2004). Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. *Int J Pharm, 277*(1–2), 3-9.

Biondi, R. M., Cheung, P. C., Casamayor, A., Deak, M., Currie, R. A., & Alessi, D. R. (2000). Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. *EMBO J, 19*(5), 979-988.

Blonk, M., Colbers, A., Poirters, A., Schouwenberg, B., & Burger, D. (2012). Effect of *Ginkgo biloba* on the pharmacokinetics of raltegravir in healthy volunteers. *Antimicrob Agents Chemother, 56*(10), 5070-5075.

Boccard, J., Bajot, F., Di Pietro, A., Rudaz, S., Boumendjel, A., Nicolle, E., & Carrupt, P. A. (2009). A 3D linear solvation energy model to quantify the affinity of flavonoid derivatives toward P-glycoprotein. *Eur J Pharm Sci, 36*(2–3), 254-264.

Boonsong, P., Laohakunjit, N., Kerdchoechuen, O., & Matta, F. B. (2011). Detection of pigments and natural colorants from Thai herbal plants for possible use as coloring dyes. *HortScience, 46*(2), 265-272.

Brandstetter, H., Kühne, A., Bode, W., Huber, R., von der Saal, W., Wirthensohn, K., & Engh, R. A. (1996). X-ray structure of active site-inhibited clotting factor Xa: implications for drug design and substrate recognition. *J Biol Chem, 271*(47), 29988-29992.

Brewer, F. K., Follit, C. A., Vogel, P. D., & Wise, J. G. (2014). *In silico* screening for inhibitors of P-glycoprotein that target the nucleotide binding domains. *Mol Pharmacol, 86*(6), 716-726.

Bruno, J. J., & Ellis, J. J. (2005). Herbal use among US elderly: 2002 National Health Interview Survey. *Ann Pharmacother, 39*(4), 643-648.

Bullangpoti, V. (2009). Botanical insecticides in Thailand: hopes and hindrances. *JBiopest, 5*(2), 75-99.

Bush, T. M., Rayburn, K. S., Holloway, S. W., Sanchez-Yamamoto, D. S., Allen, B. L., Lam, T., So, B. K., Tran de, H., Greyber, E. R., Kantor, S., & Roth, L. W. (2007). Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. *Altern Ther Health Med, 13*(2), 30-35.

Cascorbi, I. (2011). P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. *Handb Exp Pharmacol,* (201), 261-283.

Chan, L. M. S., Lowes, S., & Hirst, B. H. (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. *Eur J Pharm Sci, 21*(1), 25-51.

Chanmahasathien, W., Ampasavate, C., Greger, H., & Limtrakul, P. (2011). Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance. *Phytomedicine, 18*(2-3), 199-204.

Chen, L., Li, Y., Yu, H., Zhang, L., & Hou, T. (2012). Computational models for predicting substrates or inhibitors of P-glycoprotein. *Drug Discov Today, 17*(7-8), 343-351.

Chen, L., Li, Y., Zhao, Q., Peng, H., & Hou, T. (2011). ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and Naive Bayesian Classification techniques. *Mol Pharm, 8*(3), 889-900.

Cho, W. C. S., & Leung, K. N. (2007). *In vitro* and *in vivo* immunomodulating and immunorestorative effects of *Astragalus membranaceus*. *J Ethnopharmacol, 113*(1), 132-141.

Chotchoungchatchai, S., Saralamp, P., Jenjittikul, T., Pornsiripongse, S., & Prathanturarug, S. (2012). Medicinal plants used with Thai Traditional Medicine in modern healthcare services: A case study in Kabchoeng Hospital, Surin Province, Thailand. *J Ethnopharmacol, 141*(1), 193-205.

Chou, K. C., Wei, D. Q., & Zhong, W. Z. (2003). Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. *Biochem Biophys Res Commun, 308*(1), 148-151.

Chung, S., Sung, M., Kim, N., Jang, J., Go, E., & Lee, H. (2005). Inhibition of P-glycoprotein by natural products in human breast cancer cells. *Arch Pharm Res, 28*(7), 823-828.

Cohen, P. A., & Ernst, E. (2010). Safety of herbal supplements: a guide for cardiologists. *Cardiovasc Ther, 28*(4), 246-253.

Comelli, M. C., Mengs, U., Schneider, C., & Prosdocimi, M. (2007). Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. *Integr Cancer Ther, 6*(2), 120-129.

Cramer, R. D., Patterson, D. E., & Bunce, J. D. (1988). Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. *J Am Chem Soc, 110*(18), 5959-5967.

Damayanti, T. A., Susilo, D., Nurlaelah, S., Sartiami, D., Okuno, T., & Mise, K. (2008). First report of Bean common mosaic virus in yam bean [*Pachyrhizus erosus* (L.) Urban] in Indonesia. *J Gen Plant Pathol, 74*(6), 438-442.

Davis, E. L., Oh, B., Butow, P. N., Mullan, B. A., & Clarke, S. (2012). Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. *Oncologist, 17*(11), 1475-1481.

de Cerqueira Lima, P., Golbraikh, A., Oloff, S., Xiao, Y., & Tropsha, A. (2006). Combinatorial QSAR modeling of P-glycoprotein substrates. *J Chem Inf Model, 46*(3), 1245-1254.

Decker, H., Schweikardt, T., & Tuczek, F. (2006). The first crystal structure of tyrosinase: all questions answered? *Angew Chem Int Ed Engl, 45*(28), 4546-4550.

Desai, P. V., Sawada, G. A., Watson, I. A., & Raub, T. J. (2013). Integration of *in silico* and *in vitro* tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. *Mol Pharm, 10*(4), 1249-1261.

Di Pietro, A., Dayan, G., Conseil, G., Steinfels, E., Krell, T., Trompier, D., Baubichon-Cortay, H., & Jault, J. M. (1999). P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships. *Braz J Med Biol Res, 32*, 925-939.

Dias, R., & de Azevedo, W. F., Jr. (2008). Molecular docking algorithms. *Curr Drug Targets, 9*(12), 1040-1047.

Dickson, C. J., Madej, B. D., Skjevik, Å. A., Betz, R. M., Teigen, K., Gould, I. R., & Walker, R. C. (2014). Lipid14: The Amber Lipid Force Field. *J Chem Theory Comput, 10*(2), 865-879.

Davis, G. D., & Vasanthi, A. H. (2015). QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBbeta). *Eur J Pharm Sci*, 76, 110-118.

Dolghih, E., Bryant, C., Renslo, A. R., & Jacobson, M. P. (2011). Predicting binding to P-glycoprotein by flexible receptor docking. *PLoS Comput Biol, 7*(6), e1002083.

Dong, S., Inoue, A., Zhu, Y., Tanji, M., & Kiyama, R. (2007). Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of *Glycyrrhiza glabra* root. *Food Chem Toxicol, 45*(12), 2470-2478.

Doyle, L., & Ross, D. D. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). *Oncogene, 22*(47), 7340-7358.

Ecker, G. F., Stockner, T., & Chiba, P. (2008). Computational models for prediction of interactions with ABC-transporters. *Drug Discov Today, 13*(7–8), 311-317.

Eisenberg, D. M., Kessler, R. C., Van Rompay, M. I., Kaptchuk, T. J., Wilkey, S. A., Appel, S., & Davis, R. B. (2001). Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. *Ann Intern Med, 135*(5), 344-351.

El-Readi, M. Z., Hamdan, D., Farrag, N., El-Shazly, A., & Wink, M. (2010). Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from *Citrus* species in human colon and leukaemia cell lines. *Eur J Pharmacol, 626*(2–3), 139-145.

Elsby, R., Surry, D. D., Smith, V. N., & Gray, A. J. (2008). Validation and application of Caco-2 assays for the *in vitro* evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. *Xenobiotica, 38*(7-8), 1140-1164.

Engdal, S., Steinsbekk, A., Klepp, O., & Nilsen, O. G. (2008). Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. *Support Care Cancer, 16*(7), 763-769.

Ernst, E., & White, A. (2000). The BBC survey of complementary medicine use in the UK. *Complement Ther Med, 8*(1), 32-36.

Estrella-Parra, E. A., Gomez-Verjan, J. C., González-Sánchez, I., Vázquez-Martínez, E. R., Vergara-Castañeda, E., Cerbón, M. A., Alavez-Solano, D., & Reyes-Chilpa, R. (2014). Rotenone isolated from *Pachyrhizus erosus* displays cytotoxicity and genotoxicity in K562 cells. *Nat Prod Res, 28*(20), 1780-1785.

Fang, J., Wu, P., Yang, R., Gao, L., Li, C., Wang, D., Wu, S., Liu, A. L., & Du, G. H. (2014). Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulation. *Acta Pharm Sin B, 4*(6), 430-437.

Fasinu, P. S., Bouic, P. J., & Rosenkranz, B. (2012). An overview of the evidence and mechanisms of herb-drug interactions. *Front Pharmacol, 3*.

Featherstone, C., Godden, D., Selvaraj, S., Emslie, M., & Took-Zozaya, M. (2003). Characteristics associated with reported CAM use in patients attending six GP practices in the Tayside and Grampian regions of Scotland: a survey. *Complement Ther Med, 11*(3), 168-176.

Feldmann, J. M., Wiemann, C. M., Sever, L., & Hergenroeder, A. C. (2008). Folk and traditional medicine use by a subset of Hispanic adolescents. *Int J Adolesc Med Health, 20*(1), 41-51.

Fenner, K. S., Troutman, M. D., Kempshall, S., Cook, J. A., Ware, J. A., Smith, D. A., & Lee, C. A. (2009). Drug-drug interactions mediated through P-glycoprotein: clinical relevance and *in vitro-in vivo* correlation using digoxin as a probe drug. *Clin Pharmacol Ther, 85*(2), 173-181.

Foster, B. C., Foster, M. S., Vandenhoek, S., Krantis, A., Budzinski, J. W., Arnason, J. T., Gallicano, K. D., & Choudri, S. (2001). An *in vitro* evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. *J Pharm Pharm Sci, 4*(2), 176-184.

Fraga, C. G., Celep, G. S., & Galleano, M. (2009). Biochemical actions of plant phenolics compounds: thermodynamic and kinetic aspects *Plant Phenolics and Human Health* (pp. 91-106): John Wiley & Sons, Inc.

Fu, D., & Arias, I. M. (2012). Intracellular trafficking of P-glycoprotein. *Int J Biochem Cell Biol, 44*(3), 461-464.

Gadhe, C. G., Kothandan, G., & Cho, S. J. (2013). *In silico* study of desmosdumotin as an anticancer agent: homology modeling, docking and molecular dynamics simulation approach. *Anticancer Agents Med Chem, 13*(10), 1636-1644.

Garrigues, A., Nugier, J., Orlowski, S., & Ezan, E. (2002). A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. *Anal Biochem, 305*(1), 106-114.

Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. *Expert Opin Drug Discov, 10*(5), 449-461.

Gillam, S. J., Jarman, B., White, P., & Law, R. (1989). Ethnic differences in consultation rates in urban general practice. *BMJ, 299*(6705), 953-957.

Giveon, S. M., Liberman, N., Klang, S., & Kahan, E. (2003). A survey of primary care physicians' perceptions of their patients' use of complementary medicine. *Complement Ther Med, 11*(4), 254-260.

Giveon, S. M., Liberman, N., Klang, S., & Kahan, E. (2004). Are people who use "natural drugs" aware of their potentially harmful side effects and reporting to family physician? *Patient Educ Couns, 53*(1), 5-11.

Gohlke, H., Hendlich, M., & Klebe, G. (2000). Predicting binding modes, binding affinities and `hot spots' for protein-ligand complexes using a knowledge-based scoring function. *Perspect Drug Discov Des, 20*(1), 115-144.

Gombar, V. K., Polli, J. W., Humphreys, J. E., Wring, S. A., & Serabjit-Singh, C. S. (2004). Predicting P-glycoprotein substrates by a quantitative structure–activity relationship model. *J Pharm Sci, 93*(4), 957-968.

Gonzalez-Stuart, A. (2011). Herbal product use by older adults. *Maturitas, 68*(1), 52-55.

Götz, A. W., Williamson, M. J., Xu, D., Poole, D., Le Grand, S., & Walker, R. C. (2012). Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized Born. *J Chem Theory Comput, 8*(5), 1542-1555.

Gouws, C., Steyn, D., Du Plessis, L., Steenekamp, J., & Hamman, J. H. (2012). Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux. *Expert Opin Drug Metab Toxicol, 8*(8), 973-984.

Gupta, V., Bhalla, Y., & Jaitak, V. (2014). Impact of ABC transporters, glutathione conjugates in MDR and their modulation by flavonoids: an overview. *Med Chem Res, 23*(1), 1-15.

Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., & Ang, C. Y. (2005). Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, *Panax ginseng* and *Ginkgo biloba*. *Drugs Aging, 22*(6), 525-539.

Gyémant, N., Tanaka, M., Antus, S., Hohmann, J., Csuka, O., Mandoky, L., & Molnar, J. (2005). *In Vitro* search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. *In Vivo, 19*(2), 367-374.

Hayeshi, R., Masimirembwa, C., Mukanganyama, S., & Ungell, A. L. (2006). The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. *Eur J Pharm Sci, 29*(1), 70-81.

Hellum, B. H., & Nilsen, O. G. (2008). *In vitro* inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. *Basic Clin Pharmacol Toxicol, 102*(5), 466-475.

Hoo, R. L., Wong, J. Y., Qiao, C., Xu, A., Xu, H., & Lam, K. S. (2010). The effective fraction isolated from *Radix Astragali* alleviates glucose intolerance, insulin resistance and hypertriglyceridemia in db/db diabetic mice through its anti-inflammatory activity. *Nutr Metab (Lond), 7*(1), 1-12.

Hu, Z., Yang, X., Ho, P., Chan, S., Heng, P., Chan, E., Duan, W., Koh, H., & Zhou, S. (2005). Herb-Drug Interactions. *Drugs, 65*(9), 1239-1282.

Huang, S. Y., Grinter, S. Z., & Zou, X. (2010). Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. *Phys Chem Chem Phys, 12*(40), 12899-12908.

Huang, T. H. W., Bebawy, M., Tran, V. H., & Roufogalis, B. D. (2007). Specific reversal of multidrug resistance to colchicine in CEM/VLB100 cells by *Gynostemma pentaphyllum* extract. *Phytomedicine, 14*(12), 830-839.

Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: visual molecular dynamics. *J Mol Graph, 14*(1), 33-38.

Inta, A., Trisonthi, P., & Trisonthi, C. (2013). Analysis of traditional knowledge in medicinal plants used by Yuan in Thailand. *J Ethnopharmacol, 149*(1), 344-351.

Izzo, A., & Ernst, E. (2001). Interactions between herbal medicines and prescribed Drugs. *Drugs, 61*(15), 2163-2175.

Izzo, A. A., Borrelli, F., & Capasso, R. (2002). Herbal medicine: the dangers of drug interaction. *Trends Pharmacol Sci, 23*(8), 358-359.

Jara, G. E., Vera, D. M., & Pierini, A. B. (2013). Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study. *J Mol Graph Model, 46*, 10-21.

Jodoin, J., Demeule, M., & Beliveau, R. (2002). Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. *Biochim Biophys Acta, 1542*(1-3), 149-159.

Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997). Development and validation of a genetic algorithm for flexible docking1. *J Mol Biol, 267*(3), 727-748.

Jones, P. M., & George, A. M. (2002). Mechanism of ABC transporters: a molecular dynamics simulation of a well characterized nucleotide-binding subunit. *Proc Natl Acad Sci USA, 99*(20), 12639-12644.

Junyaprasert, V. B., Soonthornchareonnon, N., Thongpraditchote, S., Murakami, T., & Takano, M. (2006). Inhibitory effect of Thai plant extracts on P-glycoprotein mediated efflux. *Phytother Res, 20*(1), 79-81.

Kaewpiboon, C., Winayanuwattikun, P., Yongvanich, T., Phuwapraisirisan, P., & Assavalapsakul, W. (2014). Effect of three fatty acids from the leaf extract of *Tiliacora triandra* on P-glycoprotein function in multidrug-resistant A549RT-eto cell line. *Pharmacogn Mag, 10*(Suppl 3), S549-S556.

Kaisoon, O., Konczak, I., & Siriamornpun, S. (2012). Potential health enhancing properties of edible flowers from Thailand. *Food Res Int, 46*(2), 563-571.

Kennedy, J. (2005). Herb and supplement use in the US adult population. *Clin Ther, 27*(11), 1847-1858.

Kharasch, E. D., Walker, A., Hoffer, C., & Sheffels, P. (2005). Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. *J Clin Pharmacol, 45*(1), 79-88.

Kim, E. i., Paliwal, S., & Wilcox, C. S. (1998). Measurements of molecular electrostatic field effects in edge-to-face aromatic interactions and CH-π interactions with implications for protein folding and molecular recognition. *J Am Chem Soc, 120*(43), 11192-11193.

Kiralj, R., & Ferreira, M. M. C. (2009). Basic validation procedures for regression models in QSAR and QSPR studies: theory and application. *J Braz Chem Soc, 20*, 770-787.

Kirchmair, J., Markt, P., Distinto, S., Wolber, G., & Langer, T. (2008). Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection--what can we learn from earlier mistakes? *J Comput Aided Mol Des, 22*(3-4), 213-228.

Kitagawa, S., Nabekura, T., & Kamiyama, S. (2004). Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. *J Pharm Pharmacol, 56*(8), 1001-1005.

Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. *Nat Rev Drug Discov, 3*(11), 935-949.

Klebe, G., Abraham, U., & Mietzner, T. (1994). Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. *J Med Chem, 37*(24), 4130-4146.

Klepsch, F., Jabeen, I., Chiba, P., & Ecker, G. F. (2010). Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters. *Curr Pharm Des, 16*(15), 1742-1752.

Klepsch, F., Vasanthanathan, P., & Ecker, G. F. (2014). Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors. *J Chem Inf Model, 54*(1), 218-229.

Kleywegt, G. J., Harris, M. R., Zou, J. Y., Taylor, T. C., Wahlby, A., & Jones, T. A. (2004). The Uppsala Electron-Density Server. *Acta Crystallogr D Biol Crystallogr, 60*(Pt 12 Pt 1), 2240-2249.

Kokubu, N., Cohen, D., & Watanabe, T. (1997). Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein. *Biochem Biophys Res Commun, 230*(2), 398-401.

Konishi, T., Satsu, H., Hatsugai, Y., Aizawa, K., Inakuma, T., Nagata, S., Sakuda, S. H., Nagasawa, H., & Shimizu, M. (2004). Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. *Br J Pharmacol, 143*(3), 379-387.

Kovalishyn, V., Aires-de-Sousa, J., Ventura, C., Elvas Leitão, R., & Martins, F. (2011). QSAR modeling of antitubercular activity of diverse organic compounds. *Chemometr Intell Lab Syst, 107*(1), 69-74.

Kramer, B., Rarey, M., & Lengauer, T. (1999). Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking. *Proteins, 37*(2), 228-241.

Kudolo, G. B., Wang, W., Javors, M., & Blodgett, J. (2006). The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. *Clin Nutr, 25*(4), 606-616.

Kuo, G. M., Hawley, S. T., Weiss, L. T., Balkrishnan, R., & Volk, R. J. (2004). Factors associated with herbal use among urban multiethnic primary care patients: a cross-sectional survey. *BMC Complement Altern Med, 4*, 18.

Kuptniratsaikul, V., Pinthong, T., Bunjob, M., Thanakhumtorn, S., Chinswangwatanakul, P., & Thamlikitkul, V. (2011). Efficacy and safety of *Derris scandens* Benth extracts in patients with knee osteoarthritis. *J Altern Complement Med, 17*(2), 147-153.

Lazaridis, T., & Karplus, M. (1999). Discrimination of the native from misfolded protein models with an energy function including implicit solvation 1. *J Mol Biol, 288*(3), 477-487.

Le Grand, S., Götz, A. W., & Walker, R. C. (2013). SPFP: Speed without compromise—A mixed precision model for GPU accelerated molecular dynamics simulations. *Comput Phys Commun, 184*(2), 374-380.

Leach, A. R., Gillet, V. J., Lewis, R. A., & Taylor, R. (2010). Three-dimensional pharmacophore methods in drug discovery. *J Med Chem, 53*(2), 539-558.

Lew, W., Chen, X., & Kim, C. U. (2000). Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. *Curr Med Chem, 7*(6), 663-672.

Li, H. B., Jiang, Y., & Chen, F. (2004). Separation methods used for *Scutellaria baicalensis* active components. *J Chromatogr B Analy. Technol Biomed Life Sci, 812*(1–2), 277-290.

Li, H., & Geng, S. (2015). Assessment of population genetic diversity of *Derris elliptica* (Fabaceae) in China using microsatellite markers. *Ind Crops Prod, 73*, 9-15.

Li, W. D., Zhang, B. D., Wei, R., Liu, J. H., & Lin, Z. B. (2008). Reversal effect of *Ganoderma lucidum* polysaccharide on multidrug resistance in K562/ADM cell line1. *Acta Pharmacol Sin, 29*(5), 620-627.

Li, X., Hu, J., Wang, B., Sheng, L., Liu, Z., Yang, S., & Li, Y. (2014). Inhibitory effects of herbal constituents on P-glycoprotein *in vitro* and *in vivo*: Herb–drug interactions mediated via P-gp. *Toxicol Appl Pharmacol, 275*(2), 163-175.

Li, Y., Revalde, J. L., Reid, G., & Paxton, J. W. (2010). Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. *Drug Metab Rev, 42*(4), 590-611.

Li, Y., Yuan, H., Yang, K., Xu, W., Tang, W., & Li, X. (2010). The structure and functions of P-glycoprotein. *Curr Med Chem, 17*(8), 786-800.

Liang, Y., Li, X., Gu, Z., Qin, P., & Ji, M. (2015). Toxicity of amorphigenin from the seeds of *Amorpha fruticosa* against the larvae of *Culex pipiens* pallens (Diptera: Culicidae). *Molecules, 20*(2), 3238-3254.

Licht, A., & Schneider, E. (2011). ATP binding cassette systems: structures, mechanisms, and functions. *Cent Eur J Biol, 6*(5), 785-801.

Lim, T. K. (2016). *Pachyrhizus erosus Edible Medicinal and Non-Medicinal Plants: Volume 10, Modified Stems, Roots, Bulbs* (pp. 465-481). Dordrecht: Springer Netherlands.

Limtrakul, P., Khantamat, O., & Pintha, K. (2004). Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by *Momordica charantia* extract. *Cancer Chemother Pharmacol, 54*(6), 525-530.

Limtrakul, P., Siwanon, S., Yodkeeree, S., & Duangrat, C. (2007). Effect of *Stemona curtisii* root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. *Phytomedicine, 14*(6), 381-389.

Lin, L. C., Wang, M. N., & Tsai, T. H. (2008). Food–drug interaction of (−)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. *Chem Biol Interact, 174*(3), 177-182.

Linardi, R. L., & Natalini, C. C. (2006). Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodymanic of therapeutic drugs. *Cienc Rural, 36*, 336-341.

Litman, T., Zeuthen, T., Skovsgaard, T., & Stein, W. D. (1997). Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. *Biochim Biophys Acta, 1361*(2), 159-168.

Liu, D. L., Li, Y. J., Yang, D. H., Wang, C. R., Xu, J., Yao, N., Zhang, X. Q., Chen, Z. S., Ye, W. C., & Zhang, D. M. (2015). *Ganoderma lucidum* derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. *Int J Oncol, 46*(5), 2029-2038.

Liu, M. Z., Zhang, Y. L., Zeng, M. Z., He, F. Z., Luo, Z. Y., Luo, J. Q., Wen, J. G., Chen, X. P., Zhou, H. H., & Zhang, W. (2015). Pharmacogenomics and herb-drug interactions: merge of future and tradition. *Evid Based Complement Alternat Med, 2015*, 8.

Liu, S., Ji, X., Gilliland, G. L., Stevens, W. J., & Armstrong, R. N. (1993). Second-sphere electrostatic effects in the active site of glutathione S-transferase. Observation of an on-face hydrogen bond between the side chain of threonine 13 and the π-cloud of tyrosine 6 and its influence on catalysis. *J Am Chem Soc, 115*(17), 7910-7911.

Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2003). Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein: direct evidence for the substrate-induced fit mechanism for drug binding. *J Biol Chem, 278*(16), 13603-13606.

Lopez, D., & Martinez-Luis, S. (2014). Marine natural products with P-glycoprotein inhibitor properties. *Mar Drugs, 12*(1), 525-546.

Love, R. A., Parge, H. E., Wickersham, J. A., Hostomsky, Z., Habuka, N., Moomaw, E. W., Adachi, T., & Hostomska, Z. (1996). The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. *Cell, 87*(2), 331-342.

Loya, A. M., Gonzalez-Stuart, A., & Rivera, J. O. (2009). Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire-based study. *Drugs Aging, 26*(5), 423-436.

Lu, P., Liu, R., & Sharom, F. J. (2001). Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. *Eur J Biochem, 268*(6), 1687-1697.

Ma, J., & Biggin, P. C. (2013). Substrate versus inhibitor dynamics of P-glycoprotein. *Proteins, 81*(9), 1653-1668.

MacLennan, A. H., Myers, S. P., & Taylor, A. W. (2006). The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. *Med J Aust, 184*(1), 27-31.

Magrane, M., & Consortium, U. (2011). UniProt Knowledgebase: a hub of integrated protein data. *Database (Oxford), 2011*.

Manas, E. S., Xu, Z. B., Unwalla, R. J., & Somers, W. S. (2004). Understanding the selectivity of genistein for human estrogen receptor-β using x-ray crystallography and computational methods. *Structure, 12*(12), 2197-2207.

Mandava, N., Oberoi, R. K., Minocha, M., & Mitra, A. K. (2010). Transporter targeted drug delivery. *J Drug Deliv Sci Technol, 20*(2), 89-99.

Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007). Concise Review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). *Oncologist, 12*(8), 927-941.

Marco, E., & Gago, F. (2007). Overcoming the inadequacies or limitations of experimental structures as drug targets by using computational modeling tools and molecular dynamics simulations. *ChemMedChem, 2*(10), 1388-1401.

Markt, P., Schuster, D., Kirchmair, J., Laggner, C., & Langer, T. (2007). Pharmacophore modeling and parallel screening for PPAR ligands. *J Comput Aided Mol Des, 21*(10-11), 575-590.

Martin, K. J., Jordan, T. R., Vassar, A. D., & White, D. B. (2002). Herbal and nonherbal alternative medicine use in Northwest Ohio. *Ann Pharmacother, 36*(12), 1862-1869.

Martins, A., Vasas, A., Schelz, Z., Viveiros, M., Molnar, J., Hohmann, J., & Amaral, L. (2010). Constituents of *Carpobrotus edulis* inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. *Anticancer Res, 30*(3), 829-835.

McPhail, D. B., Hartley, R. C., Gardner, P. T., & Duthie, G. G. (2003). Kinetic and stoichiometric assessment of the antioxidant activity of flavonoids by electron spin resonance spectroscopy. *J Agric Food Chem, 51*(6), 1684-1690.

Miller, B. R., McGee, T. D., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA.py: an efficient program for end-state free energy calculations. *J Chem Theory Comput, 8*(9), 3314-3321.

Mirzaie, S., Chupani, L., Asadabadi, E. B., Shahverdi, A. R., & Jamalan, M. (2013). Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design. *EXCLI J, 12*, 168-183.

Miyazawa, A., Fujiyoshi, Y., & Unwin, N. (2003). Structure and gating mechanism of the acetylcholine receptor pore. *Nature, 423*(6943), 949-955.

Molassiotis, A., Fernadez-Ortega, P., Pud, D., Ozden, G., Scott, J. A., Panteli, V., V., Margulies, A., Browall, M., Magri, M., Selvekerova, S., Madsen, E., Milovics, L., Bruyns, I., Gudmundsdottir, G., Hummerston, S., Ahmad, A. M., Platin, N., Kearney, N., & Patiraki, E. (2005). Use of complementary and alternative medicine in cancer patients: a European survey. *Ann Oncol, 16*(4), 655-663.

Mora, A., Komander, D., van Aalten, D. M. F., & Alessi, D. R. (2004). PDK1, the master regulator of AGC kinase signal transduction. *Semin Cell Dev Biol, 15*(2), 161-170.

Moussally, K., Oraichi, D., & Berard, A. (2009). Herbal products use during pregnancy: prevalence and predictors. *Pharmacoepidemiol Drug Saf, 18*(6), 454-461.

Mueller, R., Rodriguez, A. L., Dawson, E. S., Butkiewicz, M., Nguyen, T. T., Oleszkiewicz, S., Bleckmann, A., Weaver, C. D., Lindsley, C. W., & Conn, P. J., Meiler, J. (2010). Identification of metabotropic glutamate receptor subtype 5 potentiators using virtual high-throughput screening. *ACS Chem Neurosci, 1*(4), 288-305.

Müller, H., Pajeva, I. K., Globisch, C., & Wiese, M. (2008). Functional assay and structure–activity relationships of new third-generation P-glycoprotein inhibitors. *Bioorg Med Chem, 16*(5), 2448-2462.

Nabekura, T., Kamiyama, S., & Kitagawa, S. (2005). Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. *Biochem Biophys Res Commun, 327*(3), 866-870.

Nonnenmacher, E., Brouant, P., Mrozek, A., Karolak-Wojciechowska, J., & Barbe, J. (2000). Structure and conformational analysis of 5,11-dibenzyldibenzo[b,f][1,5]diazocine-6,12-dione. A novel approach for new chemosensitizers. *J Mol Struct, 522*(1–3), 263-269.

Nordeng, H., Bayne, K., Havnen, G. C., & Paulsen, B. S. (2011). Use of herbal drugs during pregnancy among 600 Norwegian women in relation to concurrent use of conventional drugs and pregnancy outcome. *Complement Ther Clin Pract, 17*(3), 147-151.

Nordeng, H., & Havnen, G. C. (2005). Impact of socio-demographic factors, knowledge and attitude on the use of herbal drugs in pregnancy. *Acta Obstet Gynecol Scand, 84*(1), 26-33.

Pal, D., & Mitra, A. K. (2006). MDR- and CYP3A4-mediated drug–herbal interactions. *Life Sci, 78*(18), 2131-2145.

Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., & Miyano, M. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. *Science, 289*(5480), 739-745.

Palestro, P. H., Gavernet, L., Estiu, G. L., & Bruno Blanch, L. E. (2014). Docking applied to the prediction of the affinity of compounds to P-glycoprotein. *Biomed Res Int, 2014*, 10.

Palmeira, A., Vasconcelos, M. H., Paiva, A., Fernandes, M. X., Pinto, M., & Sousa, E. (2012). Dual inhibitors of P-glycoprotein and tumor cell growth: (Re)discovering thioxanthones. *Biochem Pharmacol, 83*(1), 57-68.

Patanasethanont, D., Nagai, J., Yumoto, R., Murakami, T., Sutthanut, K., Sripanidkulchai, B. O., Yenjai, C., & Takano, M. (2007). Effects of *Kaempferia parviflora* extracts and their flavone constituents on P-glycoprotein function. *J Pharm Sci, 96*(1), 223-233.

Penzotti, J. E., Lamb, M. L., Evensen, E., & Grootenhuis, P. D. J. (2002). A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. *J Med Chem, 45*(9), 1737-1740.

Perez-Sanchez, H., & Wenzel, W. (2011). Optimization methods for virtual screening on novel computational architectures. *Curr Comput Aided Drug Des., 7*(1), 44-52.

Petrescu, A. J., Milac, A. L., Petrescu, S. M., Dwek, R. A., & Wormald, M. R. (2004). Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. *Glycobiology, 14*(2), 103-114.

Phan, H. T. T., Yoda, T., Chahal, B., Morita, M., Takagi, M., & Vestergaard, M. d. C. (2014). Structure-dependent interactions of polyphenols with a biomimetic membrane system. *Biochim Biophys Acta, 1838*(10), 2670-2677.

Picking, D., Younger, N., Mitchell, S., & Delgoda, R. (2011). The prevalence of herbal medicine home use and concomitant use with pharmaceutical medicines in Jamaica. *J Ethnopharmacol, 137*(1), 305-311.

Pitchakarn, P., Ohnuma, S., Pintha, K., Pompimon, W., Ambudkar, S. V., & Limtrakul, P. (2012). Kuguacin J isolated from *Momordica charantia* leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance. *J Nutr Biochem, 23*(1), 76-84.

Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O., & Serabjit-Singh, C. S. (2001). Rational use of *in vitro* P-glycoprotein assays in Ddrug discovery. *J Pharmacol Exp Ther, 299*(2), 620-628.

Prajapati, R., Singh, U., Patil, A., Khomane, K. S., Bagul, P., Bansal, A. K., & Sangamwar, A. T. (2013). *In silico* model for P-glycoprotein substrate prediction: insights from molecular dynamics and *in vitro* studies. *J Comput Aided Mol Des, 27*(4), 347-363.

Raji, M. A., Kuo, Y. F., Snih, S. A., Sharaf, B. M., & Loera, J. A. (2005). Ethnic differences in herb and vitamin/mineral use in the elderly. *Ann Pharmacother, 39*(6), 1019-1023.

Ramu, A., & Ramu, N. (1992). Reversal of multidrug resistance by phenothiazines and structurally related compounds. *Cancer Chemother Pharmacol, 30*(3), 165-173.

Ramu, A., & Ramu, N. (1994). Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds. *Cancer Chemother Pharmacol, 34*(5), 423-430.

Rautio, J., Humphreys, J. E., Webster, L. O., Balakrishnan, A., Keogh, J. P., Kunta, J. R., Serabjit-Singh, C. J., & Polli, J. W. (2006). *In vitro* p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. *Drug Metab Dispos, 34*(5), 786-792.

Ravven, S. E., Zimmerman, M. B., Schultz, S. K., & Wallace, R. B. (2011). 12-month herbal medicine use for mental health from the national Comorbidity Survey Replication (NCS-R). *Ann Clin Psychiatry, 23*(2), 83-94.

Roe, D. R., & Cheatham, T. E. (2013). PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. *J Chem Theory Comput, 9*(7), 3084-3095.

Rosenblatt, M., & Mindel, J. (1997). Spontaneous hyphema associated with ingestion of *Ginkgo biloba* extract. *N Engl J Med, 336*(15), 1108-1108.

Ruschitzka, F., Meier, P. J., Turina, M., Luscher, T. F., & Noll, G. (2000). Acute heart transplant rejection due to Saint John's wort. *Lancet, 355*(9203), 548-549.

Sadeque, A. J. M., Wandel, C., He, H., Shah, S., & Wood, A. J. J. (2000). Increased drug delivery to the brain by P-glycoprotein inhibition. *Clin Pharmacol Ther, 68*(3), 231-237.

Saeed, M., Kadioglu, O., Khalid, H., Sugimoto, Y., & Efferth, T. (2015). Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking. *J Nutr Biochem, 26*(1), 44-56.

Salam, N. K., Nuti, R., & Sherman, W. (2009). Novel method for generating structure-based pharmacophores using energetic analysis. *J Chem Inf Model, 49*(10), 2356-2368.

Salama, N. N., Scott, K. R., & Eddington, N. D. (2004). The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents. *Int J Pharm, 273*(1–2), 135-147.

Salomon-Ferrer, R., Götz, A. W., Poole, D., Le Grand, S., & Walker, R. C. (2013). Routine microsecond Mmolecular dynamics simulations with AMBER on GPUs. 2. explicit solvent Particle Mesh Ewald. *J Chem Theory Comput, 9*(9), 3878-3888.

Salsbury Jr, F. R. (2010). Molecular dynamics simulations of protein dynamics and their relevance to drug discovery. *Curr Opin Pharmacol, 10*(6), 738-744.

Saokaew, S., Suwankesawong, W., Permsuwan, U., & Chaiyakunapruk, N. (2011). Safety of herbal products in Thailand. *Drug Saf, 34*(4), 339-350.

Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006). Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. *Physiol Rev, 86*(4), 1179-1236.

Sauna, Z. E., & Ambudkar, S. V. (2007). About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. *Mol Cancer Ther, 6*(1), 13-23.

Saw, J. T., Bahari, M. B., Ang, H. H., & Lim, Y. H. (2006). Herbal use amongst multiethnic medical patients in Penang Hospital: pattern and perceptions. *Med J Malaysia, 61*(4), 422-432.

Schoen, C., Osborn, R., Doty, M. M., Bishop, M., Peugh, J., & Murukutla, N. (2007). Toward higher-performance health systems: adults' health care experiences in seven countries, 2007. *Health Aff (Millwood), 26*(6), w717-734.

Schwab, D., Fischer, H., Tabatabaei, A., Poli, S., & Huwyler, J. (2003). Comparison of *in vitro* P-glycoprotein screening assays: recommendations for their use in drug discovery. *J Med Chem, 46*(9), 1716-1725.

Sharma, M., Sharma, S., Sharma, P., Kumar, A., & Bhadoriya, K. (2014). QSAR and pharmacophore approach on substituted imidazole derivatives as angiotensin II receptor antagonists. *Med Chem Res, 23*(2), 660-681.

Sharom, F. J., Liu, R., Romsicki, Y., & Lu, P. (1999). Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies. *Biochim Biophys Acta, 1461*(2), 327-345.

Shayanfar, S., Shayanfar, A., & Ghandadi, M. (2016). Image-based analysis to predict the activity of tariquidar analogs as P-glycoprotein inhibitors: the importance of external validation. *Arch Pharm, 349*(2), 124-131.

Sheu, M. T., Liou, Y. B., Kao, Y. H., Lin, Y. K., & Ho, H. O. (2010). A quantitative structure-activity relationship for the modulation effects of flavonoids on P-glycoprotein-mediated transport. *Chem Pharm Bull, 58*(9), 1187-1194.

Shoeb, M. (2006). Anticancer agents from medicinal plants. *Bangladesh J Pharmacol, 1*(2), 35-41.

Shukla, A., Sharma, P., Prakash, O., Singh, M., Kalani, K., Khan, F., Bawankule, D. U., Luqman, S., & Srivastava, S. K. (2014). QSAR and docking studies on capsazepine derivatives for immunomodulatory and anti-inflammatory activity. *PLoS One, 9*(7), e100797.

Sinxadi, P., & Blockman, M. (2008). Possible herbal medicine-drug interactions in the perioperative period. *Continuing Medical Education, 26*(3), 157.

Smith, M. B., Christensen, N., Wang, S., Strohecker, J., Day, J. D., Weiss, J. P., Crandall, B. G., Osborn, J. S., Anderson, J. L., Horne, B. D., Muhlestein, J. B., Lappe, D. L., Moss, H., Oliver, J., Viau, K., & Bunch, T. J. (2010). Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. *Cardiology, 116*(1), 61-69.

Sornsuvit, C., Phosuya, C., Jaroonwanichkul, D., & Piriyachananusorn, N. (2012). The use of herbal and dietary supplements and potential interactions with drugs in patients with chronic diseases. *Thai Pharmaceutical and Health Science Journal, 7*(4), 149-154.

Sosnik, A. (2013). Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review. *Adv Drug Deliv Rev, 65*(13–14), 1828-1851.

Sousa, I. J., Ferreira, M. J. U., Molnár, J., & Fernandes, M. X. (2013). QSAR studies of macrocyclic diterpenes with P-glycoprotein inhibitory activity. *Eur J Pharm Sci, 48*(3), 542-553.

Sousa, I. J., Ferreira, M. J., Molnar, J., & Fernandes, M. X. (2013). QSAR studies of macrocyclic diterpenes with P-glycoprotein inhibitory activity. *Eur J Pharm Sci, 48*(3), 542-553.

Sreelatha, T., Hymavathi, A., Rama Subba Rao, V., Devanand, P., Usha Rani, P., Madhusudana Rao, J., & Suresh Babu, K. (2010). A new benzil derivative from *Derris scandens*: Structure-insecticidal activity study. *Bioorg Med Chem Lett, 20*(2), 549-553.

Srinivas, K. S., & Aparna, A. S. (2012). High performance thin layer chromatographic determination of chrysin in *Oroxylum Indicum* Vent. from different geographical Regions of India. *E-Journal of Chemistry, 9*(1), 313-317.

Srivalli, K. M. R., & Lakshmi, P. K. (2012). Overview of P-glycoprotein inhibitors: a rational outlook. *Braz J Pharm Sci, 48*, 353-367.

Sukhaphirom, N., Vardhanabhuti, N., Chirdchupunseree, H., Pramyothin, P., & Jianmongkol, S. (2013). Phyllanthin and hypophyllanthin inhibit function of P-gp but not MRP2 in Caco-2 cells. *J Pharm Pharmacol, 65*(2), 292-299.

Sun, H. (2005). A Naive Bayes Classifier for prediction of multidrug resistance reversal activity on the basis of atom typing. *J Med Chem, 48*(12), 4031-4039.

Sun, H., Li, Y., Shen, M., Tian, S., Xu, L., Pan, P., Guan, Y., & Hou, T. (2014). Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. *Phys Chem Chem Phys, 16*(40), 22035-22045.

Sun, J., He, Z. G., Cheng, G., Wang, S. J., Hao, X. H., & Zou, M. J. (2004). Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. *Med Sci Monit, 10*(1), RA5-14.

Suzuki, H., & Sugiyama, Y. (2000). Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. *Eur J Pharm Sci, 12*(1), 3-12.

Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. *Nat Rev Drug Discov, 5*(3), 219-234.

Szakács, G., Váradi, A., Özvegy-Laczka, C., & Sarkadi, B. (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). *Drug Discov Today, 13*(9–10), 379-393.

Szewczyk, P., Tao, H., McGrath, A. P., Villaluz, M., Rees, S. D., Lee, S. C., Doshi, R., Urbatsch, I. L., Zhang, Q., & Chang, G. (2015). Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein. *Acta Crystallogr D Biol Crystallogr, 71*(Pt 3), 732-741.

Taipalensuu, J., Törnblom, H., Lindberg, G., Einarsson, C., Sjöqvist, F., Melhus, H., Garberg, P., Sjöström, B., Lundgren, B., & Artursson, P. (2001). Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 Cell monolayers. *J Pharmacol Exp Ther, 299*(1), 164-170.

Takahashi, L. H., Radhakrishnan, R., Rosenfield, R. E., Meyer, E. F., & Trainor, D. A. (1989). Crystal structure of the covalent complex formed by a peptidyl *α,α*-difluoro-*β*-keto amide with porcine pancreatic elastase at 1.78-Å resolution. *J Am Chem Soc, 111*(9), 3368-3374.

Takano, M., Yumoto, R., & Murakami, T. (2006). Expression and function of efflux drug transporters in the intestine. *Pharmacol Ther, 109*(1–2), 137-161.

Takeda, Y., Sarai, A., & Rivera, V. M. (1989). Analysis of the sequence-specific interactions between Cro repressor and operator DNA by systematic base substitution experiments. *Proc Natl Acad Sci USA, 86*(2), 439-443.

Tarirai, C., Viljoen, A. M., & Hamman, J. H. (2012). Effects of dietary fruits, vegetables and a herbal tea on the *in vitro* transport of cimetidine: Comparing the Caco-2 model with porcine jejunum tissue. *Pharm Biol, 50*(2), 254-263.

Taylor, J. R., & Wilt, V. M. (1999). Probable antagonism of warfarin by green tea. *Ann Pharmacother, 33*(4), 426-428.

van den Berg, S. J., Serra-Majem, L., Coppens, P., & Rietjens, I. M. (2011). Safety assessment of plant food supplements (PFS). *Food Funct, 2*(12), 760-768.

Varma, M. V. S., Ashokraj, Y., Dey, C. S., & Panchagnula, R. (2003). P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. *Pharmacol Res, 48*(4), 347-359.

Velayutham, P., Babu, A., & Liu, D. (2008). Green tea catechins and cardiovascular health: an update. *Curr Med Chem., 15*(18), 1840-1850.

Venkataramanan, R., Komoroski, B., & Strom, S. (2006). *In vitro* and *in vivo* assessment of herb drug interactions. *Life Sci, 78*(18), 2105-2115.

Verkhivker, G. M., Bouzida, D., Gehlhaar, D. K., Rejto, P. A., Arthurs, S., Colson, A. B., Freer, S. T., Larson, V., Luty, B. A., Marrone, T., & Rose, P. W. (2000). Deciphering common failures in molecular docking of ligand-protein complexes. *J Comput Aided Mol Des, 14*(8), 731-751.

Wang, Y. H., Li, Y., Yang, S. L., & Yang, L. (2005). An *in silico* approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network. *J Comput Aided Mol Des, 19*(3), 137-147.

Wang, Z., Chen, Y., Liang, H., Bender, A., Glen, R. C., & Yan, A. (2011). P-glycoprotein substrate models using support vector machines based on a comprehensive data set. *J Chem Inf Model, 51*(6), 1447-1456.

Warren, G. L., Andrews, C. W., Capelli, A. M., Clarke, B., LaLonde, J., Lambert, M. H., Lindvall, M., Nevins, N., Semus, S. F., Senger, S., Tedesco, G., Wall, I. D., Woolven, J. M., Peishoff, C. E., & Head, M. S. (2006). A critical assessment of docking programs and scoring functions. *J Med Chem, 49*(20), 5912-5931.

Waszkowycz, B. (2008). Towards improving compound selection in structure-based virtual screening. *Drug Discov Today, 13*(5–6), 219-226.

Wei, F., Liu, S. K., Liu, X. Y., Li, Z. J., Li, B., Zhou, Y. L., Zhang, H. Y., & Li, Y. W. (2013). Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. *Eur J Clin Microbiol Infect Dis, 32*(5), 657-669.

Wheaton, A. G., Blanck, H. M., Gizlice, Z., & Reyes, M. (2005). Medicinal herb use in a population-based survey of adults: prevalence and frequency of use, reasons for use, and use among their children. *Ann Epidemiol, 15*(9), 678-685.

Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak Vinkovic, D., & Jhoti, H. (2003). Crystal structure of human cytochrome P450 2C9 with bound warfarin. *Nature, 424*(6947), 464-468.

Williamson, E. (2003). Drug interactions between herbal and prescription medicines. *Drug Saf, 26*(15), 1075-1092.

Wink, M., Ashour, M. L., & El-Readi, M. Z. (2012). Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents. *Front Microbiol, 3*, 130.

Wise, J. G. (2012). Catalytic transitions in the Human MDR1 P-glycoprotein drug binding sites. *Biochemistry, 51*(25), 5125-5141.

Wolber, G., & Langer, T. (2004). LigandScout: 3-D Pharmacophores derived from protein-bound ligands and their use as virtual screening filters. *J Chem Inf Model, 45*(1), 160-169.

Wongrattanakamon, P., Lee, V. S., Nimmanpipug, P., & Jiranusornkul, S. (2016). Nucleotide-binding domain 1 modelling: A novel molecular docking approach for screening of P-glycoprotein inhibitory activity of bioflavonoids. *Chemical Data Collections, 2*, 10-16.

Wongwanakul, R., Vardhanabhuti, N., Siripong, P., & Jianmongkol, S. (2013). Effects of rhinacanthin-C on function and expression of drug efflux transporters in Caco-2 cells. *Fitoterapia, 89*(0), 80-85.

Wu, J., Li, X., Cheng, W., Xie, Q., Liu, Y., & Zhao, C. (2009). Quantitative Structure Activity Relationship (QSAR) approach to multiple drug resistance (MDR) modulators based on combined hybrid system. *QSAR Comb Sci, 28*(9), 969-978.

Xu, Y., Zhi, F., Xu, G., Tang, X., Lu, S., Wu, J., & Hu, Y. (2012). Overcoming multidrug-resistance *in vitro* and *in vivo* using the novel P-glycoprotein inhibitor 1416. *Biosci Rep, 32*(6), 559-566.

Xue, Y., Yap, C. W., Sun, L. Z., Cao, Z. W., Wang, J. F., & Chen, Y. Z. (2004). Prediction of P-glycoprotein substrates by a support vector machine approach. *J Chem Inf Comput Sci, 44*(4), 1497-1505.

Yadav, D. K., Meena, A., Srivastava, A., Chanda, D., Khan, F., & Chattopadhyay, S. K. (2010). Development of QSAR model for immunomodulatory activity of natural coumarinolignoids. *Drug Des Devel Ther, 4*, 173-186.

Yan, A., Chong, Y., Wang, L., Hu, X., & Wang, K. (2011). Prediction of biological activity of Aurora-A kinase inhibitors by multilinear regression analysis and support vector machine. *Bioorg Med Chem Lett, 21*(8), 2238-2243.

Yan, A., Wang, Z., & Cai, Z. (2008). Prediction of human intestinal absorption by GA feature selection and support vector machine regression. *Int J Mol Sci, 9*(10), 1961.

Yang, Z., Wu, D., Bui, T., & Ho, R. J. Y. (2008). A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. *J Pharmacol Exp Ther, 327*(2), 474-481.

Zeino, M., Saeed, M. E. M., Kadioglu, O., & Efferth, T. (2014a). The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter. *Invest New Drugs, 32*(4), 618-625.

Zhang, L., Strong, J. M., Qiu, W., Lesko, L. J., & Huang, S. M. (2006). Scientific perspectives on drug transporters and their role in drug interactions. *Mol Pharm, 3*(1), 62-69.

Zhang, S., & Morris, M. E. (2003). Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. *J Pharmacol Exp Ther, 304*(3), 1258-1267.

Zhang, W., & Laursen, R. A. (1998). Structure-function relationships in a type I antifreeze polypeptide: the role of threonine methyl and hydroxyl groups in antifreeze activity. *J Biol Chem, 273*(52), 34806-34812.

Zhang, W., Tan, T. M. C., & Lim, L. Y. (2007). Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. *Drug Metab Dispos, 35*(1), 110-115.

Zhang, Y., Guo, X., Lin, E. T., & Benet, L. Z. (1998). Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. *Drug Metab Dispos, 26*(4), 360-366.

Zhang, Z. J., Tan, Q. R., Tong, Y., Wang, X. Y., Wang, H. H., Ho, L. M., Wong, H. K., Feng, Y. B., Wang, D., Ng, R., McAlonan, G. M., Wang, C. Y., & Wong, V. T. (2011). An epidemiological study of concomitant use of Chinese medicine and antipsychotics in schizophrenic patients: implication for herb-drug interaction. *PLoS One, 6*(2), e17239.

Zhao, Y., Wang, L., Bao, Y., & Li, C. (2007). A sensitive method for the detection and quantification of ginkgo flavonols from plasma. *Rapid Commun Mass Spectrom, 21*(6), 971-981.

Zhong, M., Xuan, S., Wang, L., Hou, X., Wang, M., Yan, A., & Dai, B. (2013). Prediction of bioactivity of ACAT2 inhibitors by multilinear regression analysis and support vector machine. *Bioorg Med Chem Lett, 23*(13), 3788-3792.

Zhou, J., Li, Y., Zhao, J., Xue, X., Wu, L., & Chen, F. (2008). Geographical traceability of propolis by high-performance liquid-chromatography fingerprints. *Food Chem, 108*(2), 749-759.

Zhou, S., Gao, Y., Jiang, W., Huang, M., Xu, A., & Paxton, J. W. (2003). Interactions of herbs with cytochrome P450. *Drug Metab Rev, 35*(1), 35-98.

Zhou, S., Huang, M., Xu, A., Yang, H., Duan, W., & Paxton, J. W. (2005). Prediction of herb–drug metabolic interactions: a simulation study. *Phytother Res, 19*(6), 464-471.

LIST OF PUBLICATIONS

1) Wongrattanakamon, P., Lee, V. S., Nimmanpipug, P., & Jiranusornkul, S. (2016). Nucleotide-binding domain 1 modelling: A novel molecular docking approach for screening of P-glycoprotein inhibitory activity of bioflavonoids. *Chemical Data Collections*, 2, 10-16.

2) Wongrattanakamon, P., Lee, V. S., Nimmanpipug, P., & Jiranusornkul, S. (2016). 3D-QSAR modelling dataset of bioflavonoids for predicting the potential modulatory effect on P-glycoprotein activity. *Data Brief*, 9, 35-42.

3) Wongrattanakamon, P., Lee, V. S., Nimmanpipug, P., & Jiranusornkul, S. (2016). Nucleotide binding domain 1 pharmacophore modeling for visualization and analysis of P-glycoprotein–flavonoid molecular interactions. *Front Biol (Beijing)*, 11(5), 391-395.

4) Wongrattanakamon, P., Lee, V. S., Nimmanpipug, P., Chansakaow, S., & Jiranusornkul, S. (2017). Insight into the molecular mechanism of P-glycoprotein mediated drug toxicity induced by bioflavonoids: an integrated computational approach. *Toxicol Mech Methods*, (in press).